Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

101. The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management

• Depending on the FeNO cutoff, the likelihood of having asthma in people ages 5 years and older increases by 2.8 to 7.0 times given a positive FeNO test result. • FeNO is modestly more accurate in diagnosing steroid-naïve asthmatics, children (ages 5-18), and nonsmokers than other patients suspected to have asthma. • FeNO results can predict which patients will respond to inhaled corticosteroid therapy. • Using FeNO to manage long-term control medications including dose titration, weaning, and monitoring (...) asthma in people ages 5 years and older. Test performance is modestly better in steroid-naïve asthmatics, children, and nonsmokers than the general population with suspected asthma. Algorithms that include FeNO measurements can help in monitoring response to anti-inflammatory or long-term control medications, including dose titration, weaning, or treatment adherence. At this time, there is insufficient evidence supporting the measurement of FeNO in children under the age of 5 as a means

2018 Effective Health Care Program (AHRQ)

102. Arbesda RespiClick - fluticasone propionate / salmeterol xinafoate - Asthma

request granted - Reconsideration requested Applicant's request for reconsideration placed on CDEC agenda December 12, 2018 CDEC Final Recommendation issued to applicant and drug plans December 19, 2018 CDEC Final Recommendation posted December 21, 2018 Final CADTH review report(s) and patient input posted January 17, 2019 Tags asthma, dry powder inhalers, respiratory, respiclick; arbesda; fluticasone propionate; salmeterol; dry powder inhaler; asthmatic; asthmatics Files Follow us: © 2019 Canadian (...) Arbesda RespiClick - fluticasone propionate / salmeterol xinafoate - Asthma fluticasone propionate / salmeterol xinafoate | CADTH.ca Find the information you need fluticasone propionate / salmeterol xinafoate fluticasone propionate / salmeterol xinafoate Last Updated: March 22, 2019 Result type: Reports Project Number: SR0540-000 Product Line: Generic Name: fluticasone propionate / salmeterol xinafoate Brand Name: Arbesda RespiClick Manufacturer: TEVA Canada Innovation Indications: Asthma

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

103. Aermony RespiClick - fluticasone propionate - Asthma

, 2018 CDEC Final Recommendation posted December 21, 2018 Final CDR review report(s) and patient input posted January 21, 2019 Tags asthma, dry powder inhalers, respiratory, aermony; fluticasone propionate; dry powder inhaler; asthmatic; asthmatics; respiclick Files Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter: (...) Aermony RespiClick - fluticasone propionate - Asthma fluticasone propionate | CADTH.ca Find the information you need fluticasone propionate fluticasone propionate Last Updated: December 21, 2018 Result type: Reports Project Number: SR0539-000 Product Line: Generic Name: fluticasone propionate Brand Name: Aermony RespiClick Manufacturer: TEVA Canada Innovation Indications: Asthma Submission Type: New Project Status: Complete Biosimilar: No Date Recommendation Issued: December 19, 2018

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

104. Effect of an Intervention to Promote Breastfeeding on Asthma, Lung Function, and Atopic Eczema at Age 16 Years: Follow-up of the PROBIT Randomized Trial Full Text available with Trip Pro

Effect of an Intervention to Promote Breastfeeding on Asthma, Lung Function, and Atopic Eczema at Age 16 Years: Follow-up of the PROBIT Randomized Trial Atopic diseases, including asthma and atopic eczema, are the most common chronic conditions of childhood.To investigate whether an intervention to promote prolonged and exclusive breastfeeding protects against asthma, atopic eczema, and low lung function in adolescence.Follow-up of the Promotion of Breastfeeding Intervention Trial (PROBIT (...) outcomes; secondary outcomes were self-reported asthma diagnosis ever, and wheezing and flexural eczema symptoms in the previous year.A total of 13 557 (79.5%) participants were followed up from September 15, 2012 to July 15, 2015. The intervention (7064 [79.7%]) and control (6493 [79.4%]) groups were similar at follow-up (3590 [50.8%] and 3391 [52.2%] male; mean [SD] age, 16.2 [0.6] and 16.1 [0.5] years, respectively). In the intervention group, 0.3% (21 of 7064) had flexural eczema on skin

2018 EvidenceUpdates

105. Benralizumab (Fasenra) - For add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype

Benralizumab (Fasenra) - For add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype Fasenra (benralizumab) 30 mg/mL Injection U.S. Department of Health and Human Services Search FDA Submit search Fasenra (benralizumab) 30 mg/mL Injection Fasenra Company: AstraZeneca Pharmaceuticals LP Application No.: 761070 Approval Date: 11/14/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

2018 FDA - Drug Approval Package

106. Fasenra - benralizumab - Asthma, severe eosinophilic

Fasenra - benralizumab - Asthma, severe eosinophilic benralizumab | CADTH.ca Find the information you need benralizumab benralizumab Last Updated: January 7, 2019 Result type: Reports Project Number: SR0561-000 Product Line: Generic Name: benralizumab Brand Name: Fasenra Manufacturer: AstraZeneca Canada Inc. Indications: Asthma, severe eosinophilic Manufacturer Requested Reimbursement Criteria 1 : For add-on maintenance treatment of adult patients with severe eosinophilic asthma who (...) are inadequately controlled with high-dose inhaled corticosteroids (ICS) and one or more additional asthma controller(s) (e.g., LABA), if one of the following clinical criteria are met: 1. Blood eosinophil count of 300 cells/L AND have experienced two or more clinically significant asthma exacerbations in the past 12 months, or 2. Blood eosinophil count of 150 cells/L and are treated chronically with oral corticosteroids (OCS). Submission Type: New Project Status: Active Biosimilar: No Date Recommendation

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

107. Asthma

Asthma Asthma - NICE CKS Share Asthma: Summary Asthma is a chronic inflammatory condition of the airways. The airways are hyper-responsive and constrict easily in response to a wide range of stimuli. This may result in coughing, wheezing, chest tightness, and shortness of breath. Asthma is a common condition. The British Lung Foundation states that 5.4 million people in the UK are receiving treatment for asthma. A diagnosis of asthma should be suspected in a person with: Wheeze, breathlessness (...) , chest tightness, and cough, particularly if symptoms are worse at night and in the early morning; occur in response to exercise, allergen exposure, and cold air; occur after taking non-steroidal anti-inflammatory drugs, or beta-blockers; occur in the absence of an upper respiratory tract infection. History of atopic disorder. Widespread wheeze (bilateral, predominantly expiratory). There is no single diagnostic test for asthma. Tests that can help support an asthma diagnosis include fractional

2018 NICE Clinical Knowledge Summaries

109. Management of Acute Exacerbation of Asthma Presenting to the Emergency Department or Urgent Care

(not statistically significant) for dex vs prednisolone (odds ratio = 0.27; 95% confidence interval = 0.07-0.98) • Study findings indicate the majority of caregivers prefer: – use of single-dose dex in tx of an acute asthma exacerbation – to have all medications at d/c from PED despite reporting ease of filling a prescription (45%) Williams, 2013 Cross-sectional Survey study 100 Parents of ED asthmatic pts, 1 - 17 yrs old, with previous use of systemic steroids for an asthma exacerbation at Medical University (...) Management of Acute Exacerbation of Asthma Presenting to the Emergency Department or Urgent Care Best Evidence Statement – BESt 213 Copyright © 2018 Cincinnati Children's Hospital Medical Center; all rights reserved. Page 1 of 15 December 1, 2018 Management of Acute Exacerbation of Asthma Presenting to the Emergency Department or Urgent Care INTRODUCTION / BACKGROUND Discharge data for pediatric patients who had presented to the emergency department had shown that patients were returning

2018 Cincinnati Children's Hospital Medical Center

110. Breaking through Restricting Bottleneck for Better Asthma Control Full Text available with Trip Pro

Breaking through Restricting Bottleneck for Better Asthma Control 29340274 2019 01 28 2450-131X 5 4 2017 Dec Journal of translational internal medicine J Transl Int Med Breaking through Restricting Bottleneck for Better Asthma Control. 192-193 10.1515/jtim-2017-0032 Zhu Ding D Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Institute of Respiratory Diseases, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. Zhang Chao C Department (...) Diseases, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. eng Journal Article 2017 12 29 Poland J Transl Int Med 101673826 2224-4018 Conflict of Interest: None declared. 2018 1 18 6 0 2018 1 18 6 0 2018 1 18 6 1 epublish 29340274 10.1515/jtim-2017-0032 jtim-2017-0032 PMC5767707 Am J Respir Crit Care Med. 2010 Jan 15;181(2):116-24 19815809 J Asthma. 2016;53(1):94-100 26383773 Respir Med. 2006 Jul;100(7):1139-51 16713224 J Pediatr Pharmacol Ther. 2017 Jul-Aug;22(4):293-299

2017 Journal of translational internal medicine

111. Evaluation of anxiety and depression in mothers of children with asthma Full Text available with Trip Pro

Evaluation of anxiety and depression in mothers of children with asthma Asthma is the most common chronic disease in childhood. Parents have an important role in managing asthma in children. Studies have shown a higher degree of depression and anxiety and lower family performance in mothers of asthmatic children in comparison with the control group.The aim of this study was to evaluate the parenting styles and also depression, anxiety and stress parameters in mothers of children (...) with asthma.This case-control study was performed on 45 mothers of 3 to 15 years old asthmatic children in the allergy clinic of Mashhad University of Medical Sciences, Mashhad, Iran, during the years of 2014 to 2016. The control group was 45 mothers of non-asthmatic children who were matched for the age of their children with the case group in the same population. The parenting styles, as well as depression and anxiety of mothers were evaluated using parenting scales, and the depression-anxiety-stress scales

2017 Electronic physician

112. Asthma. (Abstract)

Asthma. Asthma-one of the most common chronic, non-communicable diseases in children and adults-is characterised by variable respiratory symptoms and variable airflow limitation. Asthma is a consequence of complex gene-environment interactions, with heterogeneity in clinical presentation and the type and intensity of airway inflammation and remodelling. The goal of asthma treatment is to achieve good asthma control-ie, to minimise symptom burden and risk of exacerbations. Anti-inflammatory (...) and bronchodilator treatments are the mainstay of asthma therapy and are used in a stepwise approach. Pharmacological treatment is based on a cycle of assessment and re-evaluation of symptom control, risk factors, comorbidities, side-effects, and patient satisfaction by means of shared decisions. Asthma is classed as severe when requiring high-intensity treatment to keep it under control, or if it remains uncontrolled despite treatment. New biological therapies for treatment of severe asthma, together

2017 Lancet

113. Stormy weather: a retrospective analysis of demand for emergency medical services during epidemic thunderstorm asthma. Full Text available with Trip Pro

Stormy weather: a retrospective analysis of demand for emergency medical services during epidemic thunderstorm asthma. To describe the demand for emergency medical assistance during the largest outbreak of thunderstorm asthma reported globally, which occurred on 21 November 2016.A time series analysis was conducted of emergency medical service caseload between 1 January 2015 and 31 December 2016. Demand during the thunderstorm asthma event was compared to historical trends for the overall (...) November, compared with a daily average of 52 during the historical period. After adjustment for temporal trends, thunderstorm asthma was associated with a 42% (95% confidence interval 40% to 44%) increase in overall caseload for the emergency medical service and a 432% increase in emergency medical attendances for acute respiratory distress symptoms. Emergency transports to hospital increased by 17% (16% to 19%) and time critical referrals from general practitioners increased by 47% (21% to 80

2017 BMJ

114. Breathing training for dysfunctional breathing in asthma: taking a multidimensional approach Full Text available with Trip Pro

Breathing training for dysfunctional breathing in asthma: taking a multidimensional approach Various breathing training programmes may be helpful for adults with asthma. The main therapeutic aim for many of these programmes is the correction of dysfunctional breathing. Dysfunctional breathing can be viewed practically as a multidimensional entity with the three key dimensions being biochemical, biomechanical and psychophysiological. The objectives of this review are to explore how each (...) of these dimensions might impact on asthma sufferers, to review how various breathing therapy protocols target these dimensions and to determine if there is evidence suggesting how breathing therapy protocols might be optimised. Databases and reference lists of articles were searched for peer-reviewed English language studies that discussed asthma or dysfunctional breathing and various breathing therapies. Biochemical, biomechanical and psychophysiological aspects of dysfunctional breathing can all potentially

2017 ERJ open research

115. Asthma: diagnosis, monitoring and chronic asthma management

Asthma: diagnosis, monitoring and chronic asthma management Asthma: diagnosis, monitoring and Asthma: diagnosis, monitoring and chronic asthma management chronic asthma management NICE guideline Published: 29 November 2017 nice.org.uk/guidance/ng80 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived (...) be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Asthma: diagnosis, monitoring and chronic asthma management (NG80) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

116. International Variation in Asthma and Bronchiolitis Guidelines Full Text available with Trip Pro

International Variation in Asthma and Bronchiolitis Guidelines Guideline recommendations for the same clinical condition may vary. The purpose of this study was to determine the degree of agreement among comparable asthma and bronchiolitis treatment recommendations from guidelines.National and international guidelines were searched by using guideline databases (eg, National Guidelines Clearinghouse: December 16-17, 2014, and January 9, 2015). Guideline recommendations were categorized as (1 (...) ) recommend, (2) optionally recommend, (3) abstain from recommending, (4) recommend against a treatment, and (5) not addressed by the guideline. The degree of agreement between recommendations was evaluated by using an unweighted and weighted κ score. Pairwise comparisons of the guidelines were evaluated similarly.There were 7 guidelines for asthma and 4 guidelines for bronchiolitis. For asthma, there were 166 recommendation topics, with 69 recommendation topics given in ≥2 guidelines. For bronchiolitis

2017 EvidenceUpdates

117. A virtual asthma clinic for children: fewer routine outpatient visits, same asthma control Full Text available with Trip Pro

A virtual asthma clinic for children: fewer routine outpatient visits, same asthma control eHealth is an appealing medium to improve healthcare and its value (in addition to standard care) has been assessed in previous studies. We aimed to assess whether an eHealth intervention could improve asthma control while reducing 50% of routine outpatient visits.In a multicentre, randomised controlled trial with a 16-month follow-up, asthmatic children (6-16 years) treated in eight Dutch hospitals were (...) children. After follow-up, symptom-free days differed statistically between the usual care and VAC groups (difference of 1.23 days, 95% CI 0.42-2.04; p=0.003) in favour of the VAC. In terms of asthma control, the Childhood Asthma Control Test improved more in the VAC group (difference of 1.17 points, 95% CI 0.09-2.25; p=0.03). No differences were found for other outcome measures.Routine outpatient visits can partly be replaced by monitoring asthmatic children via eHealth.Copyright ©ERS 2017.

2017 EvidenceUpdates

118. Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma

Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma Comparative Effectiveness Review Number 202 Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma eComparative Effectiveness Review Number 202 Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-00005-I (...) and safety of bronchial thermoplasty (BT), a procedure that uses heat to remove muscle tissue from the airways of adults with moderate to severe asthma. BT is usually given as three treatments 3 weeks apart. Key Messages • BT along with standard medical management, compared to medical management alone, may improve asthma control and quality of life, but evidence is insufficient to determine impact on asthma exacerbations. • BT along with standard medical management, compared to a similar procedure

2017 Effective Health Care Program (AHRQ)

119. Exemplar clinical pathways for a stratified approach to severe asthma

Exemplar clinical pathways for a stratified approach to severe asthma The Academy of Medical Sciences 4 ? ? ? ? ? ? ? The Academy of Medical Sciences 5 The Academy of Medical Sciences 6 The Academy of Medical Sciences 7 Introduction to a stratified approach ? ? ? ? The Academy of Medical Sciences 8 The Academy of Medical Sciences 9 ? ? ? The Academy of Medical Sciences 10 The Academy of Medical Sciences 11 The Academy of Medical Sciences 12 The Academy of Medical Sciences 13 Adopting

2017 Academy of Medical Sciences

120. Nebulized Hypertonic Saline for Asthma in Adults and Children: Clinical Effectiveness

Nebulized Hypertonic Saline for Asthma in Adults and Children: Clinical Effectiveness Nebulized Hypertonic Saline for Asthma in Adults and Children: Clinical Effectiveness | CADTH.ca Find the information you need Nebulized Hypertonic Saline for Asthma in Adults and Children: Clinical Effectiveness Nebulized Hypertonic Saline for Asthma in Adults and Children: Clinical Effectiveness Published on: October 31, 2017 Project Number: RA0937-000 Product Line: Research Type: Devices and Systems Report

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review